A detailed history of Allworth Financial LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Allworth Financial LP holds 105 shares of BEAM stock, worth $2,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105
Previous 105 -0.0%
Holding current value
$2,655
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$21.22 - $32.66 $2,100 - $3,233
-99 Reduced 48.53%
105 $2,000
Q1 2024

Apr 25, 2024

SELL
$23.46 - $45.07 $8,492 - $16,315
-362 Reduced 63.96%
204 $6,000
Q4 2023

Jan 24, 2024

SELL
$17.69 - $30.76 $9,534 - $16,579
-539 Reduced 48.78%
566 $15,000
Q3 2023

Oct 31, 2023

BUY
$23.01 - $32.46 $15,784 - $22,267
686 Added 163.72%
1,105 $26,000
Q2 2023

Jul 18, 2023

BUY
$29.32 - $35.99 $1,671 - $2,051
57 Added 15.75%
419 $13,000
Q1 2023

Apr 18, 2023

SELL
$30.15 - $48.79 $904 - $1,463
-30 Reduced 7.65%
362 $11,000
Q4 2022

Jan 13, 2023

SELL
$36.73 - $51.6 $110 - $154
-3 Reduced 0.76%
392 $0
Q3 2022

Oct 18, 2022

SELL
$39.79 - $70.31 $2,785 - $4,921
-70 Reduced 15.05%
395 $19,000
Q1 2022

Apr 22, 2022

BUY
$53.73 - $82.16 $3,384 - $5,176
63 Added 15.67%
465 $27,000
Q2 2021

Aug 02, 2021

SELL
$64.12 - $128.71 $12,824 - $25,742
-200 Reduced 33.22%
402 $52,000
Q1 2021

Apr 29, 2021

BUY
$71.28 - $120.75 $9,979 - $16,905
140 Added 30.3%
602 $48,000
Q4 2020

Jan 26, 2021

BUY
$22.24 - $95.63 $5,382 - $23,142
242 Added 110.0%
462 $38,000
Q3 2020

Nov 03, 2020

BUY
$19.0 - $30.57 $4,180 - $6,725
220 New
220 $5,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.